Samsung Medical Center
| República da Coreia | Turki | Austria | |
| Terapi sel T CAR | dari $385,000 | dari $150,000 | dari $350,000 |
Bookimed tidak menambah biaya tambahan dalam harga Terapi sel T CAR. Tarif berasal dari daftar harga resmi klinik. Anda membayar langsung di klinik untuk Terapi sel T CAR Anda saat tiba.
Bookimed berkomitmen pada keselamatan Anda. Kami hanya bekerja dengan institusi medis yang menjaga standar internasional tinggi dalam Terapi sel T CAR dan memiliki izin yang dibutuhkan untuk melayani pasien internasional di seluruh dunia.
Bookimed menawarkan bantuan ahli gratis. Koordinator medis pribadi mendukung Anda sebelum, selama, dan setelah perawatan, menyelesaikan semua masalah Anda. Anda tidak pernah sendirian dalam perjalanan Terapi sel T CAR Anda.
Pusat yang memenuhi syarat di Korea Selatan harus menerima persetujuan dari Kementerian Keamanan Pangan dan Obat-obatan (MFDS) untuk memberikan terapi sel CAR-T. Fasilitas utama yang berwenang meliputi Samsung Medical Center, Seoul National University Hospital, dan Seoul St. Mary's Hospital. Institusi-institusi ini mengelola produk komersial seperti Kymriah untuk pasien limfoma dan leukemia.
Wawasan Pakar Bookimed: Samsung Medical Center melayani lebih dari 2.000.000 pasien setiap tahun dan mempertahankan infrastruktur tingkat kepresidenan. Volume yang tinggi ini menghasilkan pengalaman yang signifikan dalam onkologi kompleks. Adopsi awal mereka terhadap pusat khusus menjadikan mereka pemimpin dalam menangani sindrom pelepasan sitokin. Perawatan khusus ini sangat penting bagi keselamatan pasien selama fase infus sel CAR-T yang agresif.
Konsensus Pasien: Pasien menekankan perlunya verifikasi resmi. Mereka menyarankan untuk menghubungi departemen onkologi secara langsung guna mengonfirmasi status persetujuan KFDA saat ini untuk terapi tertentu. Banyak yang menyarankan untuk menyiapkan anggaran lebih dari $300.000 dan merencanakan masa tinggal selama 6 minggu.
Kementerian Keamanan Pangan dan Obat-obatan Korea Selatan telah menyetujui empat terapi sel CAR-T utama: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Carvykti (ciltacabtagene autoleucel), dan Rimqarto (anbalcabtagene autoleucel). Produk-produk ini mengobati limfoma tertentu dan mieloma multipel. Pemberian dilakukan di pusat-pusat khusus seperti Samsung Medical Center.
Wawasan Pakar Bookimed: Meskipun persetujuan meningkat, logistik manufaktur tetap menjadi hambatan yang signifikan. Data menunjukkan pasien sering menunggu lebih dari 6 bulan untuk produk impor. Pusat-pusat terkemuka seperti Samsung Medical Center mengelola jadwal ini dengan lebih baik karena volume pasien yang tinggi. Mereka melayani lebih dari 2.000.000 pasien setiap tahun dan memiliki protokol aferesis yang mapan.
Konsensus Pasien: Pasien menekankan perlunya memverifikasi kemampuan rumah sakit sejak dini. Mereka sering melaporkan bahwa cakupan asuransi tertinggal dari persetujuan regulasi, menjadikan biaya pribadi sebagai kekhawatiran utama.
Asuransi Kesehatan Nasional Korea Selatan menanggung terapi sel CAR-T terutama untuk limfoma sel B besar difus yang kambuh atau refrakter dan leukemia limfoblastik akut sel B pediatrik. Cakupan biasanya berlaku mulai dari pengobatan lini ketiga di bawah pedoman ketat Layanan Asuransi Kesehatan Nasional di pusat medis terakreditasi.
Wawasan Pakar Bookimed: Samsung Medical Center melayani lebih dari 2.000.000 pasien setiap tahun dan memegang akreditasi KOIHA untuk keselamatan. Volume mereka yang tinggi menunjukkan bahwa mereka mengelola penggantian biaya Asuransi Kesehatan Nasional yang kompleks dan persetujuan tingkat rumah sakit secara efisien. Pasien harus memverifikasi keganasan spesifik mereka terhadap perjanjian pembagian risiko terbaru di pusat-pusat berkapasitas tinggi tersebut.
Konsensus Pasien: Pasien melaporkan bahwa meskipun cakupan leukemia pediatrik dapat diandalkan, banyak orang dewasa dengan mieloma multipel menghadapi biaya pribadi. Sebagian besar menyarankan untuk bersiap menghadapi kopay 10% hingga 20% bahkan ketika asuransi menyetujui pengobatan tersebut.
Korea Selatan secara aktif merekrut untuk uji klinis sel CAR-T yang menargetkan limfoma, leukemia, dan kanker hati. Studi terkemuka termasuk uji coba ALPHA3 untuk limfoma sel B dan uji coba fase 1 EU307 untuk karsinoma hepatoseluler. Pusat pendaftaran termasuk Samsung Medical Center dan Seoul National University Hospital.
Wawasan Pakar Bookimed: Meskipun banyak uji coba global menggunakan ClinicalTrials.gov, pusat-pusat di Korea Selatan sering memprioritaskan registri CRIS lokal. Samsung Medical Center, yang melayani lebih dari 2.000.000 pasien setiap tahun, sering mengoperasikan jalur uji coba internal. Memeriksa daftar Pusat Kanker spesifik mereka biasanya mengungkapkan lebih banyak slot aktif daripada basis data internasional.
Konsensus Pasien: Banyak yang menemukan bahwa informasi uji coba terutama tersedia dalam bahasa Korea. Kontak langsung dengan departemen internasional rumah sakit tingkat pertama lebih efektif daripada mencari di daftar online publik.
Common side effects of CAR T-cell therapy in Korea include Cytokine Release Syndrome (CRS) and neurological toxicity (ICANS). Specialists at centres like Seoul's Samsung Medical Center manage these effects during a mandatory 10-day monitoring period. This monitoring helps protect patient safety and supports long-term recovery.
Bookimed Expert Insight: Data shows Korean oncology centres focus heavily on immediate safety. They require patients to stay within 30 minutes of the hospital for 30 days. Facilities like Samsung Medical Center provide integrated ICU access. They also keep tocilizumab immediately available to neutralise severe immune reactions.
Patient Consensus: Patients in Korea find that intensive 10-day hospital monitoring helps catch early symptoms quickly. These symptoms include fever and confusion. Most people report that brain fog and fatigue can last for several months. This happens after the initial hospital stay.
Republic of Korea clinics provide CAR T-cell therapy for specific relapsed or refractory blood cancers. Approved treatments target B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, and multiple myeloma. Specialist centres like Samsung Medical Center use MFDS-approved protocols including Kymriah and domestically developed therapies.
Bookimed Expert Insight: While most international patients seek Kymriah, Korea’s domestic drug Rimqarto shows significant promise for lymphoma. Samsung Medical Center’s partnership with the Mayo Clinic means these local protocols meet global clinical standards. This dual-track availability provides more options. It benefits patients who do not respond to standard CAR T drugs.
Patient Consensus: Patients find the process for blood cancers very established in Seoul. They recommend sticking to MFDS-approved therapies and major medical centres. Trials for solid tumours are interesting but still seen as experimental by most families.
South Korea offers Kymriah, Yescarta, and Carvykti for haematologic malignancies like leukaemia and multiple myeloma. Clinically approved domestic options include Rimqarto, developed by Curocell. Specialists at Samsung Medical Centre administered the first treatments. Costs range from $385,000 to $515,000.
Bookimed Expert Insight: Samsung Medical Centre serves over 2 million outpatients annually. It also houses one of Asia’s largest cancer centres. Its partnership with the Mayo Clinic means CAR T-cell protocols meet rigorous international standards. Choosing a high-volume centre like this is vital. It helps manage the intensive care required after infusion.
Patient Consensus: Patients find that accessing Kymriah in Korea is more affordable than in Australia. This is due to local insurance coverage. Many travellers look for clinical trials in Seoul. They seek newer therapies that are not yet available commercially.
South Korea offers numerous clinical trials for CAR T-cell therapy. These focus on blood cancers and solid tumours. Institutions such as Samsung Medical Center and Seoul National University Hospital lead these studies. Recent local approvals like Anbal-cel provide additional options alongside global therapies like Kymriah.
Bookimed Expert Insight: Samsung Medical Center serves over 2 million outpatients annually. It also maintains a direct partnership with the Mayo Clinic. This connection often gives patients faster access to international trial protocols. It also offers collaborative expertise for complex cases. It is a major differentiator for those seeking high-volume clinical experience in Seoul.
Patient Consensus: Korea's Regenerative Medicine Law allows access to cell therapies for severe conditions outside traditional trials. Patients suggest that during consultations, clinics should distinguish CAR T-cell therapy from standard stem cell treatments.
South Korea National Health Insurance (NHI) covers CAR T-cell therapy for eligible residents with specific blood cancers. Since April 2022, Kymriah is reimbursed for third-line treatment of diffuse large B-cell lymphoma. It also covers paediatric acute lymphoblastic leukaemia in the third line. Coverage significantly reduces costs for those enrolled in the national scheme.
Bookimed Expert Insight: While NHI offers massive savings, these benefits only apply to residents. International patients usually pay full price, which ranges from $385,000 to $515,000. Samsung Medical Center, Asia's largest cancer centre, manages these complex cases regularly.
Patient Consensus: Korea provides high coverage for cancer through NHI. Foreigners without residency should prepare for costs 20 times higher than local residents. Major hospitals in Seoul offer the most reliable guidance on insurance eligibility.
CAR T-cell therapy in Korea faces several challenges. These include high costs (from $385,000 to $515,000). Other challenges are limited access outside Seoul and complex logistics for cell manufacturing. Patients must also manage severe clinical toxicities like Cytokine Release Syndrome (CRS). They need specialised intensive care facilities for this.
Bookimed Expert Insight: While costs are high, Bookimed data shows Samsung Medical Centre manages over 2 million outpatients annually. They partner with the Mayo Clinic and use integrated digital imaging systems. Together, these help manage complex CAR T-cell cases. Patients should confirm specific product availability as Korean approval varies by cancer type.
Patient Consensus: Success rates for severe relapsed cases can sit around 40% in Korea. Recovery requires strict isolation and 4+ months of precautions like eating only cooked food. Patients frequently have low blood counts and weakened immunity. This can last for months after treatment.